What you should know:
1. Todos is developing TM-C1, a blood-based diagnostic test for colon cancer.
2. Todos is in the midst of studying TM-C1.
3. When elaborating on the next steps for TM-C1, Dr. Weiss referenced Exact Sciences’ developmental path.
“Exact Sciences has shown successful adoption for their colon cancer stool test and we believe we can replicate their roadmap to success with a simple blood test,” Dr. Weiss said.
4. The company has blood-based tests for breast and other cancers in development.
More articles on gastroenterology::
Pennsylvania’s $12.5M tax on ASCs could cause dozens to close, lawmaker says — 5 key points
Novant Health makes $1.8B impact with network of outpatient facilities, medical centers
Vermont Gov. signs ASC licensure bill into law — 5 key details
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
